GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.87 $1.65 Thursday, 18th Apr 2024 ADAP stock ended at $0.90. This is 8.98% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 13.44% from a day low at $0.87 to a day high of $0.99.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2023-10-18 $0.621 $0.629 $0.565 $0.587 810 423
2023-10-17 $0.646 $0.662 $0.610 $0.629 604 982
2023-10-16 $0.660 $0.667 $0.621 $0.665 657 319
2023-10-13 $0.669 $0.669 $0.640 $0.656 537 755
2023-10-12 $0.689 $0.699 $0.650 $0.669 477 095
2023-10-11 $0.671 $0.700 $0.671 $0.680 206 210
2023-10-10 $0.671 $0.719 $0.671 $0.680 330 819
2023-10-09 $0.701 $0.710 $0.675 $0.686 245 122
2023-10-06 $0.700 $0.735 $0.700 $0.713 165 376
2023-10-05 $0.704 $0.729 $0.700 $0.720 268 433
2023-10-04 $0.754 $0.770 $0.669 $0.728 878 502
2023-10-03 $0.711 $0.800 $0.695 $0.760 594 246
2023-10-02 $0.780 $0.800 $0.710 $0.750 451 830
2023-09-29 $0.770 $0.81 $0.750 $0.780 207 861
2023-09-28 $0.80 $0.81 $0.765 $0.786 184 994
2023-09-27 $0.735 $0.82 $0.735 $0.80 459 026
2023-09-26 $0.755 $0.783 $0.718 $0.760 389 056
2023-09-25 $0.770 $0.775 $0.720 $0.760 302 856
2023-09-22 $0.770 $0.785 $0.750 $0.783 252 006
2023-09-20 $0.738 $0.753 $0.723 $0.745 188 969
2023-09-19 $0.739 $0.748 $0.680 $0.728 1 227 052
2023-09-18 $0.784 $0.790 $0.740 $0.741 404 174
2023-09-15 $0.735 $0.82 $0.735 $0.81 769 830
2023-09-14 $0.83 $0.85 $0.777 $0.81 498 261
2023-09-13 $0.770 $0.82 $0.766 $0.80 153 647
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT